AccueilPRE • NASDAQ
add
Prenetics Global Ltd
Dernière clôture
4,50 $
Variation sur la journée
4,43 $ - 4,43 $
Plage sur l'année
2,85 $ - 7,84 $
Capitalisation boursière
53,16 M USD
Volume moyen
6,93 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | 5,94 M | 4,32 % |
Charges d'exploitation | 14,38 M | 0,52 % |
Résultat net | -10,72 M | 50,83 % |
Marge bénéficiaire nette | -180,46 | 52,87 % |
Bénéfice par action | — | — |
EBITDA | -9,51 M | 13,59 % |
Taux d'imposition effectif | 0,79 % | — |
Bilan
Total des actifs
Total du passif
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 63,89 M | -67,46 % |
Total des actifs | 233,31 M | -16,93 % |
Total du passif | 42,30 M | -30,22 % |
Total des capitaux propres | 191,00 M | — |
Actions en circulation | 12,22 M | — |
Ratio cours/valeur comptable | 0,29 | — |
Rentabilité des actifs | -11,12 % | — |
Retour sur capitaux | -13,33 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | juin 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -10,72 M | 50,83 % |
Trésorerie (opérations) | — | — |
Trésorerie (invest.) | — | — |
Trésorerie (financement) | — | — |
Variation nette en trésorerie | — | — |
Flux de trésorerie dispo. | — | — |
À propos
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Date de fondation
2014
Site Web
Employés
322
